I want to thank everyone here for indulging my compulsive behaviour, or better still "enabling" might be a better description, like buying an alcoholic a beer....

Until we get some new meat to chew on I'm going to be posting less....

Right now the way I see it everything is basically priced in...the Hepalink deal, the financing, even the potential for an orphan indication, its all built into the price somewhere in the $2-$2.30 range.

I'm looking forward to seeing what happens around the Epicongress event in Boston. To my way of thinking that has real potential to get us moving again by increasing demand for shares of RVX. Let's face it, development stage biotech is hot....but epigentics is little understood. Trying to get noticed in a sea of promises to end all manner of diseases isn't easy, and having to explain what Epigenetics is doesn't help matters. A lot of people...if they don't understand something, they're not going to risk $$$ on it.

Rodman and Renshaw strikes me as a waste of time, money and effort. They'll be competeing for attention with companies that people understand.....there's one hope though, if the PPS is moving, then it can add fuel to the fire. There's nothing like the "potential" for massive gains that will get people to investigate and learn. But if the PPS is floundering in early September.....meh.

But I'm getting ahead of myself.....let's get to Boston first and see what happens.